NEO Stock Analysis: NeoGenomics | NASDAQ
Diagnostics & Research | NASDAQ, USA | Market Cap: 2.129m USD | 12M Return: 170.1% | US64049M2098 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 40.7M
Qual. Beats: 0
Rev. Trend: 99.9%
Qual. Beats: 1
Warnings
Tailwinds
Seasonality 11.6 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
NeoGenomics, Inc. (NEO) is a specialty diagnostics company that operates a network of cancer-focused testing laboratories across the United States and the United Kingdom. Founded in 2001 and headquartered in Fort Myers, Florida, the company provides a broad menu of oncology-related testing services to hospitals, academic centers, pathologists, oncologists, clinicians, pharmaceutical firms, and other clinical laboratories. Its service offerings span cytogenetics, fluorescence in-situ hybridization (FISH), flow cytometry, immunohistochemistry with digital imaging, molecular testing, and morphologic analysis, and it also supports pharmaceutical clients oncology drug discovery and commercialization programs.
As a small-cap player in the Health Care Services sub-industry, NeoGenomics operates within the outsourced clinical diagnostics sector, where independent labs perform complex, specialized tests on behalf of hospitals and physicians rather than the tests being conducted in-house. Its focus on oncology makes it a niche provider in a broader U.S. clinical laboratory market that also includes larger, diversified competitors.
- Pharma services revenue accelerates with oncology clinical trial demand
- Medicare reimbursement cuts pressure clinical testing margins
- Competition intensifies from liquid biopsy and molecular diagnostic peers
| Net Income: -51.9m TTM > 0 and > 6% of Revenue |
| FCF/TA: -0.01 > 0.02 and ΔFCF/TA 0.83 > 1.0 |
| NWC/Revenue: 35.96% < 20% (prev 42.40%; Δ -6.44% < -1%) |
| CFO/TA 0.02 > 3% & CFO 22.0m > Net Income -51.9m |
| Net Debt (377.0m) to EBITDA (12.9m): 29.25 < 3 |
| Current Ratio: 3.60 > 1.5 & < 3 |
| Outstanding Shares: last quarter (26.2m) vs 12m ago 2.25% < -2% |
| Gross Margin: 42.92% > 18% (prev 43.91%; Δ -0.99% > 0.5%) |
| Asset Turnover: 55.81% > 50% (prev 49.44%; Δ 6.37% > 0%) |
| Interest Coverage Ratio: -20.37 > 6 (EBIT TTM -52.6m / Interest Expense TTM 2.58m) |
| A: 0.20 (Total Current Assets 381.5m - Total Current Liabilities 105.9m) / Total Assets 1.35b |
| B: -0.33 (Retained Earnings -448.7m / Total Assets 1.35b) |
| C: -0.04 (EBIT TTM -52.6m / Avg Total Assets 1.37b) |
| D: 1.39 (Book Value of Equity 785.7m / Total Liabilities 565.6m) |
| Altman-Z'' = 1.46 = BB |
| DSRI: 1.03 (Receivables 175.4m/153.6m, Revenue 766.3m/689.2m) |
| GMI: 1.02 (GM 43.91% / 42.92%) |
| AQI: 1.00 (AQ_t 0.59 / AQ_t-1 0.60) |
| SGI: 1.11 (Revenue 766.3m / 689.2m) |
| TATA: -0.05 (NI -51.9m - CFO 22.0m) / TA 1.35b) |
| Beneish M = -2.91 (Cap -4..+1) = A |
As of August 13, 2026, the stock is trading at USD 16.42 with a total of 1,047,038 shares traded. Over the past week, the price has changed by +4.39%, over one month by +16.37%, over three months by +87.66% and over the past year by +170.07%.
Current recommended Stop Loss: 14.50 (which is 11.7% or 2.4 ATR below the current price).
NeoGenomics has received a consensus analysts rating of 4.17. Therefore, it is recommended to buy NEO.
- StrongBuy: 6
- Buy: 2
- Hold: 4
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 19.7 | 20.1% |
P/E Forward = 222.2222
P/S = 2.7781
P/B = 2.6636
P/EG = 2.0871
Revenue TTM = 766.3m USD
EBIT TTM = -52.6m USD
EBITDA TTM = 12.9m USD
Long Term Debt = 374.2m USD (from longTermDebt, last quarter)
Short Term Debt = 5.43m USD (from shortTermDebt, last quarter)
Debt = 522.5m USD (from shortLongTermDebtTotal, last quarter) + Leases 74.1m
Net Debt = 377.0m USD (calculated: Debt 522.5m - CCE 145.5m)
Enterprise Value = 2.51b USD (2.13b + Debt 522.5m - CCE 145.5m)
Interest Coverage Ratio = -20.37 (Ebit TTM -52.6m / Interest Expense TTM 2.58m)
EV/FCF = -340.7x (Enterprise Value 2.51b / FCF TTM -7.36m)
FCF Yield = -0.29% (FCF TTM -7.36m / Enterprise Value 2.51b)
FCF Margin = -0.96% (FCF TTM -7.36m / Revenue TTM 766.3m)
Net Margin = -6.77% (Net Income TTM -51.9m / Revenue TTM 766.3m)
Gross Margin = 42.92% ((Revenue TTM 766.3m - Cost of Revenue TTM 437.4m) / Revenue TTM)
Gross Margin QoQ = 45.56% (prev 43.32%)
Tobins Q-Ratio = 1.85 (Enterprise Value 2.51b / Total Assets 1.35b)
Interest Expense / Debt = 0.49% (Interest Expense 2.58m / Debt 522.5m)
Taxrate = 21.0% (US federal default 21%)
NOPAT = -41.5m (EBIT -52.6m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 3.60 (Total Current Assets 381.5m / Total Current Liabilities 105.9m)
Debt / Equity = 0.66 (Debt 522.5m / totalStockholderEquity, last quarter 785.7m)
Debt / EBITDA = 29.25 (Net Debt 377.0m / EBITDA 12.9m)
Debt / FCF = -51.25 (negative FCF - burning cash) (Net Debt 377.0m / FCF TTM -7.36m)
Total Stockholder Equity = 822.3m (last 4 quarters mean from totalStockholderEquity)
RoA = -3.78% (Net Income -51.9m / Total Assets 1.35b)
RoE = -6.31% (Net Income TTM -51.9m / Total Stockholder Equity 822.3m)
RoCE = -4.39% (EBIT -52.6m / Capital Employed (Equity 822.3m + L.T.Debt 374.2m))
RoIC = -3.42% (negative operating profit) (NOPAT -41.5m / Invested Capital 1.21b)
WACC = 6.40% (E(2.13b)/V(2.65b) * Re(7.88%) + D(522.5m)/V(2.65b) * Rd(0.49%) * (1-Tc(0.21)))
Discount Rate = 7.88% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 94.73 | Cagr: 1.65%
[DCF] Fair Price = unknown (Cash Flow -7.36m)
EPS Correlation: N/A | EPS CAGR: N/A | SUE: 0.57 | # QB: 0
Revenue Correlation: 99.91 | Revenue CAGR: 10.75% | SUE: 1.97 | # QB: 1
EPS current Quarter (2026-09-30): EPS=0.05 | Chg30d=-4.29% | Revisions=+0% | Analysts=11
EPS current Year (2026-12-31): EPS=0.18 | Chg30d=-0.16% | Revisions=+0% | GrowthEPS=+52.3% | GrowthRev=+10.6%
EPS next Year (2027-12-31): EPS=0.34 | Chg30d=-7.24% | Revisions=+25% | GrowthEPS=+85.1% | GrowthRev=+10.0%
[Analyst] Revisions Ratio: +6% (up=7, down=6)